Last updated on February 2018

Effects of Sitaglpitin on Endothelial Function During the OGTT in T2DM


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: NIDDM
  • Age: Between 20 - 80 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Provision of informed consent before any study specific procedures
  • Type II diabetes who have inadequate glycaemic control (6.5%HbA1c9.0%)
  • Age from 20 to 80 years old
  • No history of using any antihyperglycemic drugs
  • No history of cardiovascular complications
  • No treatment or treatment with stable doses of lipid-lowering, antihypertensive, and antiplatelet agents for at least 3 months prior to randomization
  • 4.5 % fasting FMD at baseline < 8.0 %

Exclusion Criteria:

  • Type I diabetes
  • Pregnancy
  • Liver disease (hepatic enzymes more than three times the upper limit of normal ranges)
  • Impairared kidney function (serum crearinine greater than 1.3 mg/dl in men, 1.2 mg/dl in women)
  • Cigarette smokers
  • Contraindications to glimepiride and sitagliptin
  • Active proliferative diabetic retinopathy

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.